Stocktoria

Schrodinger, Inc. SDGR

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-02-06 · LEI

Schrodinger, Inc. financials (annual)

Revenue
$85.5M $108.1M $137.9M $181.0M $216.7M $207.5M $255.9M 2019202020212022202320242025
Net income
-$24.6M -$24.5M -$100.4M -$149.2M $40.7M -$187.1M -$103.3M 2019202020212022202320242025
Free cash flow
-$27.9M $14.2M -$77.8M -$127.7M -$150.1M -$164.7M $12.5M 2019202020212022202320242025

Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$255.9M$207.5M$216.7M$181.0M$137.9M$108.1M$85.5M
Gross profit$142.6M$132.1M$140.7M$101.0M$65.6M$63.5M$49.1M
R&D expense$173.1M$201.8M$181.8M$126.4M$90.9M$64.7M$39.4M
Operating income-$166.9M-$209.3M-$177.4M-$146.8M-$111.4M-$60.9M-$38.7M
Income tax$939,000$1.4M$2.2M$63,000$411,000$345,000-$291,000
Net income-$103.3M-$187.1M$40.7M-$149.2M-$100.4M-$24.5M-$24.6M
EPS (diluted)$-1.41$-2.57$0.54$-2.10$-1.42$-0.41
Operating cash flow$13.9M-$157.4M-$136.7M-$119.7M-$70.7M$16.8M-$26.1M
Free cash flow$12.5M-$164.7M-$150.1M-$127.7M-$77.8M$14.2M-$27.9M
Cash & equivalents$230.5M$147.3M$155.3M$90.5M$120.3M$202.3M$26.0M
Total assets$726.2M$823.2M$803.0M$688.6M$756.5M$746.3M$155.3M
Total liabilities$362.1M$401.8M$254.4M$240.7M$199.4M$122.2M$57.0M
Shareholders' equity$364.1M$421.4M$548.6M$447.9M$557.1M$624.0M-$93.4M

Growth · year-over-year · Revenue CAGR 20%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue growth+23.3%-4.2%+19.7%+31.2%+27.6%+26.4%
Net income growth-559.5%
EPS growth-575.9%
Free cash flow growth-647.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.